chrX-153905582-G-C

Variant summary

Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong

The NM_000054.7(AVPR2):​c.76G>C​(p.Glu26Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. 15/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).

Frequency

Genomes: not found (cov: 26)

Consequence

AVPR2
NM_000054.7 missense

Scores

17

Clinical Significance

Uncertain significance criteria provided, single submitter U:1

Conservation

PhyloP100: 0.390
Variant links:
Genes affected
AVPR2 (HGNC:897): (arginine vasopressin receptor 2) This gene encodes the vasopressin receptor, type 2, also known as the V2 receptor, which belongs to the seven-transmembrane-domain G protein-coupled receptor (GPCR) superfamily, and couples to Gs thus stimulating adenylate cyclase. The subfamily that includes the V2 receptor, the V1a and V1b vasopressin receptors, the oxytocin receptor, and isotocin and mesotocin receptors in non-mammals, is well conserved, though several members signal via other G proteins. All bind similar cyclic nonapeptide hormones. The V2 receptor is expressed in the kidney tubule, predominantly in the distal convoluted tubule and collecting ducts, where its primary property is to respond to the pituitary hormone arginine vasopressin (AVP) by stimulating mechanisms that concentrate the urine and maintain water homeostasis in the organism. When the function of this gene is lost, the disease Nephrogenic Diabetes Insipidus (NDI) results. The V2 receptor is also expressed outside the kidney although its tissue localization is uncertain. When these 'extrarenal receptors' are stimulated by infusion of a V2 selective agonist (dDAVP), a variety of clotting factors are released into the bloodstream. The physiologic importance of this property is not known - its absence does not appear to be detrimental in NDI patients. The gene expression has also been described in fetal lung tissue and lung cancer associated with alternative splicing. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_benign. Variant got -2 ACMG points.

PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.06294745).

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
AVPR2NM_000054.7 linkuse as main transcriptc.76G>C p.Glu26Gln missense_variant 3/4 ENST00000646375.2
AVPR2NM_001146151.3 linkuse as main transcriptc.76G>C p.Glu26Gln missense_variant 3/3
AVPR2NR_027419.2 linkuse as main transcriptn.465+412G>C intron_variant, non_coding_transcript_variant

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
AVPR2ENST00000646375.2 linkuse as main transcriptc.76G>C p.Glu26Gln missense_variant 3/4 NM_000054.7 P1P30518-1

Frequencies

GnomAD3 genomes
Cov.:
26
GnomAD4 exome
Cov.:
35
GnomAD4 genome
Cov.:
26

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link

Submissions by phenotype

Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingAmbry GeneticsOct 12, 2022The c.76G>C (p.E26Q) alteration is located in exon 2 (coding exon 2) of the AVPR2 gene. This alteration results from a G to C substitution at nucleotide position 76, causing the glutamic acid (E) at amino acid position 26 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.082
BayesDel_addAF
Benign
-0.27
T
BayesDel_noAF
Benign
-0.63
CADD
Benign
6.6
DANN
Benign
0.82
DEOGEN2
Benign
0.33
T;T;.;T;.
FATHMM_MKL
Benign
0.16
N
LIST_S2
Benign
0.51
.;.;T;T;T
M_CAP
Benign
0.031
D
MetaRNN
Benign
0.063
T;T;T;T;T
MetaSVM
Benign
-1.0
T
MutationAssessor
Benign
2.0
M;M;.;M;M
MutationTaster
Benign
1.0
N;N;N
PrimateAI
Benign
0.36
T
PROVEAN
Benign
-0.17
.;N;N;N;N
REVEL
Benign
0.058
Sift
Benign
0.34
.;T;T;T;T
Sift4G
Benign
0.55
.;T;T;T;T
Polyphen
0.0010
B;B;.;B;B
Vest4
0.087, 0.079
MutPred
0.24
Loss of phosphorylation at S23 (P = 0.1393);Loss of phosphorylation at S23 (P = 0.1393);Loss of phosphorylation at S23 (P = 0.1393);Loss of phosphorylation at S23 (P = 0.1393);Loss of phosphorylation at S23 (P = 0.1393);
MVP
0.77
MPC
0.50
ClinPred
0.099
T
GERP RS
-0.60
Varity_R
0.15
gMVP
0.48

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

No publications associated with this variant yet.

Other links and lift over

hg19: chrX-153171036; API